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mTOR is a downstream mediator in the PI3K/Akt signalling pathway, which plays a critical role in regulating basic cellular functions.
These include cell proliferation, survival, mobility and angiogenesis. Rapamycin and its analogues (CCI-779, RAD001 and AP23573)
have specific antagonistic action on the function of mTOR. This leads to inhibition of the downstream signalling elements and results
in the cell cycle arrest in the G1 phase. This group of drugs may have a place in Oncology for the treatment of cancers, which occur as
a result of increased activity of the PI3 kinase/Akt/m-TOR pathway. The basic structure of the pathway was reviewed in this article,
together with results of the clinical studies targeting mTOR for cancer therapy. This is an exciting area for development and poses
many challenges to researchers.
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THE PI3-KINASES, AND mTOR
The phosphoinositide 3-kinase (PI3K) family of enzymes is
responsible for the production of 3-phosphoinositide lipid second
messengers including phosphoinositol trisphosphate (PIP3). The
pathway controls a cascade of signals that regulates many basic
cellular properties, including proliferation, survival, motility, and
angiogenesis. Evidence implicating the role of deregulation of the
PI3K in oncogenesis includes the finding that PI3K activity is
linked to viral oncogenes such as v-src (Li et al, 1997), v-abl, v-ros,
ras (Chan et al, 1999). Multiple mechanisms for the activation of
the PI3K-AKT/PKB pathway have been identified in a range of
cancers (Mills et al, 2001, 2003). These include mutation and
silencing of the pTEN tumour suppressor gene that encodes a lipid
phosphatase that reverses the PI3K reaction, and amplification,
overexpression and activation of the AKT/PKB. The activated AKT
phosphorylates a variety of target proteins. One of these, called
BAD, is a protein that normally encourages cells to undergo
apoptosis. By phosphorylating BAD, AKT inactivates it, thereby
promoting cell survival (Chao and Korsmeyer, 1998). AKT also
promotes cell survival by inhibiting other activators of apoptosis,
in some cases by inhibiting the transcription of the genes that
encode them. Various approaches are being taken to block PI3K
signalling in human cancer. One strategy is to inhibit individual
oncogenic kinases within the PI3K pathway. The two prototype
PI3K inhibitors are wortmannin (a natural product) and the
chromenone LY294002, both have shown anticancer activity in
vitro and in animal models, but have significant limitation for
clinical use because of the lack of kinase specificity and metabolic
instability (Workman, 2003).
During the mid-1990s, through molecular cloning efforts, a
novel family of high molecular mass kinases whose catalytic
domains bore a clear resemblance to those of PI3Ks was identified.
Based on this primary sequence homology, the newly identified
kinases were named PI3K and related kinases (PIKKs). The
members of the PIKK family are found in all eukaryotic cells, and
accumulating data from genetic, biochemical, and pharmacological
studies suggest that these proteins play key roles in fundamental
cellular processes, including proliferation and genome surveillance
(Hartwell and Kastan, 1994; Paulovich et al, 1997). Based on
primary sequence alone, it seemed reasonable to predict that the
PIKKs were either lipid kinases or dual lipid–protein kinases, but
the evidence that PIKKs transmit signals exclusively through the
phosphorylation of protein substrate is increasing rapidly. The
PIKKs includes three subfamilies: the TOR subfamily, ataxia
telangiectasia, the ATM gene product, and the DNA-dependent
protein kinase.
The first members of the PIKK family to be molecularly cloned
were TOR1 and TOR2 from studies in budding yeast cells
(Saccharomyces cerevisiae). The isolation of cDNAs encoding a
mammalian ortholog, mTOR, followed shortly (Brown et al, 1994).
FUNCTIONS Of THE MAMMALIAN TOR PROTEIN
The members of the Target of Rapamycin (TOR) subfamily are
uniquely targeted for inhibition by rapamycin, a feature that has
greatly facilitated efforts to understand their functions in
eukaryotic cells. Rapamycin is a macrolide antibiotic with
antifungal and immunosuppressive properties, which has been
approved as an immunosuppressant drug for organ transplanta-
tion (Abraham and Wiederrecht, 1996). Rapamycin binds to a
highly conserved cytoplasmic receptor FK506-binding protein-12
(FKBP12). This FKBP12-rapamycin complex binds to and inhibits
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expressed by either component alone. Rapamycin’s mechanism of
action represents a solution for the design of a small molecule
inhibitor bearing a high level of specificity for a large polypetide
target. The FKBP12 receptor positions rapamycin in the optimal
orientation to interact with the TOR proteins and also supplies
structural determinants that contribute to the affinity and
specificity of this interaction.
Studies of rapamycin-treated or TOR-depleted yeast and
mammalian cells have shown that loss of TOR function leads to
arrest in early G1 phase (Barbet et al, 1996). Furthermore, these
cells show a severe reduction in protein synthesis resembling those
cells in G0 phase, a response normally triggered by starvation.
These findings suggested that the TOR proteins play a general role
in the translational control of gene expression during cell growth,
and the overall rate of protein synthesis in response to nutrient
supply and other environmental changes.
Unlike yeast cells, mammalian cells display widely varying
sensitivities to the growth-inhibition of rapamycin. A typical target
cell for rapamycin is the activated T lymphocyte, which undergoes
G1 to S phase progression in response to IL-2 or T-cell growth-
promoting cytokines. IL-2-stimulated T cells accumulate in the
mid/late G1 phase of the cell cycle in the presence of very low
concentration of rapamycin (less than 10nM) (Morice et al,
1993a,b).
ROLE OF mTOR IN p70 s6 KINASE ACTIVATION AND
THE APPLICATION OF THE KINASE AS A
BIOLOGICAL END POINT FOR CLINICAL STUDY
There are two proteins whose phosphorylation state has been
shown to be regulated by mTOR. The first targeted protein is p70
s6 kinase, a serine-threonine kinase that is activated in response to
a broad range of mitogenic stimuli. Rapamycin blocks both the
phosphorylation and activation of p70 s6K in mammalian cells.
The second end point for the mTOR-dependent phosphorylation
pathway is the translational-repressor protein PHAS-1 (also
termed 4E-BP). Both proteins participate in the regulation of
protein synthesis in cells stimulated by either mitogens or
hormones.
The regulation of p70 s6k by upstream protein kinases is
complex (Proud, 1996). It is clear that treatment with rapamycin
quickly and efficiently inhibits the de novo phosphorylation of p70
s6k induced by hormonal stimuli, as well as the phosphorylation of
previously activated p70 s6k. The level of p70 s6k activity in
peripheral blood mononuclear cells has been showed to correlate
with the efficacy of RAD001, an mTOR inhibitor in clinical studies
(Lane, 2003). It has been suggested that this biomarker strategy
can be used to define the minimal effective dose for clinical studies
of mTOR inhibitors.
In summary, both PI3K and its downstream serine-threonine
kinase AKT participate in mTOR activation by growth factors such
as hormones and insulin (Gingras et al, 1998; Scott et al, 1998).
This places mTOR in a signalling cascade implicated in the
abnormal growth and survival of certain cancer cells. Therefore,
rapamycin or other mTOR kinase inhibitors may have significant
anticancer activity in tumours driven by activated PI3K or AKT or
both (Dancey, 2000) (Figure 1).
mTOR INHIBITORS IN CLINICAL DEVELOPMENT
Results of clinical studies had been reported using the three
rapamycin analogues: RAD001 (Novartis) (Lane, 2003), AP23573
(ARIAD Pharmaceuticals) (Mita et al, 2004), and CCI-779 (Wyeth)
(Yu et al, 2001). The pharmacological action of these rapamycin
analogues, like rapamycin, is mediated through its binding to the
intracellular protein FKBP12 and subsequent inhibition of the
protein kinase mTOR.
Sirolimus, the major metabolite of CCI-779, also binds to
FKBP12. Exposure to the sirolimus metabolite is substantial, with a
mean value of approximately 1.4- to 2.3-fold that of CCI-779
following i.v. administration to as high as 13.8- to 34.5-fold the
values seen following oral administration. It is, at present, unclear
what proportion of the anticancer activity of CCI-779 is due to
CCI-779, or its metabolite sirolimus. Clinical development on the
use of mTOR inhibitors in oncology is advancing rapidly. CCI-779
was the first to enter the field. Results from its clinical studies may
contribute to understanding some of the challenges involved in
designing trials for this group of drugs.
CCI-779: preclinical studies
A study of a panel of breast cancer cell lines showed differences in
the sensitivity to the antiproliferative effects of CCI-779 (Yu et al,
2001). Sensitive cell lines were oestrogen receptor positive, or
lacking in expression of the tumour suppressor gene pTEN and/or
overexpression of the oncogene Her-2/neu. CCI-779 inhibited
mTOR functions in both sensitive and resistant cell lines.
Treatment of sensitive lines with CCI-779 resulted in a decrease
in cyclin-D and c-myc levels and an increase in p27 Kip-1 levels.
There was a correlation between the activation of the Akt pathway
and sensitivity to CCI-779. These results suggest that mTOR may
be a good target for the treatment of breast cancer. Especially in
patients with tumours that are driven by the activation of the Akt


















Figure 1 A diagram of the mTOR pathway.
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dependence, or the loss of the pTEN tumour suppressor function.
CCI-779: clinical studies
The proposed mechanism of action by CCI-779 as an inhibitor of
mTOR, and its properties as a cytostatic agent may be useful in
clinical oncology. A Phase 1 study where the drug was given once a
week intravenously (Alexandre et al, 1999) antitumour activity was
demonstrated in patients with advanced breast cancer in the study.
BREAST CANCER
A phase 2 safety and efficacy trial of two levels of CCI-779 in
women with advanced breast cancer was initiated in 2001.
Enrolment was completed in February 2002 with 109 patients
recruited (Chan et al, 2003a). The majority of patients received
more than two lines of prior chemotherapy, including anthracy-
clines and/or taxanes. Results of the study were presented at the
American Society of Clinical Oncology annual meeting in 2003.
There was no significant difference in terms of efficacy between the
patients who received 75 or 250mgweek
 1 doses. However,
toxicity was higher in the 250mgweek
 1 group and a dose
reduction was required in 45.1% of patients in this group
compared with 28.6% in the 75mgweek
 1 group. The most
common reason for study discontinuation was lethargy and
depression (75mg, N¼5/42; 250mg, N¼12/43). Adverse events
were generally grade 1 or grade 2 and often resolved without
discontinuing treatment. Grade 3 and 4 toxicities were rare, and
included: depression, mucositis, diarrhoea, transiently raised GGT,
hyperglycaemia, hypokalaemia, leucopenia, and infection. In terms
of efficacy, among the 98 evaluable patients, objective response
rate (WHO criteria) was 10% (10/98), and the median response
duration was 5.4 months (95% CI: 3.8–7.2). Clinical benefit
(partial response and stable disease over 2 months) was noted in
36 patients (37%).
The most striking finding from the first analysis of the biological
phenotype (as reported by individual centres) of those breast
cancers in the study, was that none of the 32 Her-2 negative
tumours showed any significant response to the treatment with
CCI-779. The value of this study is the demonstration of significant
clinical activity of CCI-779, with manageable toxicities, in
advanced breast cancer.
We studied tumours preserved in paraffin blocks from our 28
patients who participated in the trial using immunohistochemical
methods (Sharma et al, 2003). Our results showed that 4/28
tumours were negative for PTEN (indicative of gene mutation),
and 3/4 of these tumours showed objective response to treatment
with CCI-779; 3/28 tumours had HER-2 gene overexpression (3þ
Herceptin Test or FISH þve), 2/3 of these tumours showed an
objective response to the drug. These findings suggest that PTEN
mutation and/or HER-2 overexpression in breast cancer may
predict response to mTOR inhibitors.
Using immunohistochemical staining of tissue microarrays, we
have also studied the expression of PTEN (wild type) and its
relationship with phosphorylated AKT, as well as with other
recognized prognostic factors (HER-2 expression, oestrogen
receptor status, histological grade, lymph node status at initial
surgery, tumour size, age, menopausal status, risk of recurrence,
and survival) in 429 cases of operable invasive breast cancer with a
minimum 5 years of follow-up (Chan et al, 2003b). We found that
7.5% of cases did not express wild-type PTEN, while 70 and 22.5%
of cases were weakly and strongly positive, respectively. The
immunohistochemical expression of PTEN was related to pAKT
levels (Po0.001) – tumours with low levels of pAKT frequently did
not express wild-type PTEN. No significant correlation was
observed between PTEN and other known prognostic factors or
patient survival. pAKT expression was inversely related to tumour
grade (Po0.001) and size (Po0.002), while a positive correlation
was seen with ER status (Po0.001). pAkt expression was not
however significantly related to patient survival nor was it an
independent prognostic factor. These data suggest that the
relationship between pAKT and PTEN is complicated in invasive
breast cancer, and that better understanding of the pathway is
necessary before we can define the predictive markers for response
to treatment with the mTOR inhibitor.
The role of PI3K/AKT/mTOR pathway may play an important
role in the development of Tamoxifen resistance in breast cancer.
Activation of the oestrogen receptor can drive the PI3K pathway
(Simoncini et al, 2000). Cross talk between erb-1 and ER has
been shown to activate the pathway, which has been associated
with oestrogen-independent transcriptional activity (Aronica and
Katzellenbogen, 1991; Pietras et al, 1995; Smith, 1998; Campbell
et al, 2001), and breast cancer cell lines with activated Akt is
resistant to the growth inhibitory effects of Tamoxifen (Degra-
fenried et al, 2002). The combination of antioestrogens and mTOR
inhibitors may improve the therapeutic index of either agent alone.
A phase 2 study comparing the use of Letrozole with or without
CCI-779 in patients with advanced breast cancer has recently
completed recruitment (Baselga et al, 2004), but it is too early to
assess the efficacy of this combination.
RENAL CELL CARCINOMA
In a randomised double-blind phase 2 study (Atkin et al, 2002);
weekly CCI-779 at three different doses (25/75/100mg) was given
once per week intravenously to patients with previously treated
advanced renal cell carcinoma. Toxicity profile was similar to that
reported from the breast cancer trial. Side effects were largely
grade 1 and 2. Overall response rate was 5%. Interestingly, there
was no significant difference between the three dose levels in terms
of efficacy, but the 25mg group has the least toxicity reported.
The combination of CCI-779 and interferon alpha was studied in
patients with advanced renal cell carcinoma (Dutcher et al, 2003).
The result showed that the combination was well tolerated, and
partial response to the treatment was observed. A large phase 3
study comparing the combination vs interferon alpha alone in this
patient population has already been started.
OTHER CLINICAL STUDIES USING mTOR
INHIBITORS: IN OTHER TUMOUR TYPES AND
USED IN COMBINATIONS WITH CYTOTOXIC
CHEMOTHERAPY
Preliminary efficacy data from the phase 1 single-agent studies
indicate antitumour activities (in addition to breast cancer and
renal cell carcinoma) of mTOR inhibitors (CCI-779, RAD001 and
AP23573) in patients with non-small-cell lung cancer, anaplastic
astrocytoma, mesothelioma, soft tissue sarcoma, cervical and
uterine cancer (O’Donnell et al, 2003; Mita et al, 2004).
There is evidence to suggest that mTOR inhibitors may be used
to overcome drug resistance to cytotoxic chemotherapeutic agents.
For example, treatment of Doxorubicin-resistant and PTEN
defective prostate cancer cells with CCI-779 has been shown to
reverse Doxorubicin resistance (Grunwald et al, 2002). There is
no clinical data available on this combination, at the present.
CCI-779 combinations with Gemcitabine and 5-Fluorouracil
(þLeucovorin) were limited by gastrointestinal events (diarrhoea,
mucositis, and nausea). In combination with Gemcitabine (day 1
and 8 of 21days cycle), the maximum tolerated dose of CCI-779
was only 15mg per sq m, and the weekly i.v. dose in the 5-
Fluorourcil combination was 75mg per sq m (Wyeth, personal
communication).
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The mTOR inhibitors have demonstrated clinical activities
in a broad spectrum of solid tumours. Unresolved challenges
to researchers include: definition of the optimal dose and
scheduling; identifying the appropriate biological end points
for dose finding studies; finding predictive markers for
tumour phenotypes likely to response to mTOR inhibitors;
and finding optimal combination treatment with other
drugs and radiotherapy. Drug development targeting the
mTOR pathway looks exciting, but a lot more work remains
to be done.
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